HERTFORDSHIRE, England, and PITTSBURGH, Feb. 19, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced that its abbreviated new drug application (ANDA) for fluticasone propionate 100, ...

The Food and Drug Administration has accepted Lannett’s abbreviated new drug application for fluticasone propionate and salmeterol inhalation powder in three strengths — a generic of GlaxoSmithKline's ...

GlaxoSmithKline plc (GSK) today announced results from the 'LABA' (long acting beta 2-agonist) safety study, AUSTRI(SAS115359). The study compared Advair ® Diskus ®, a combination of the LABA, ...

Lannett has submitted an ANDA to the Food and Drug Administration for its strategic partner, Respirant's fluticasone propionate and salmeterol inhalation powder (100/50 mcg, 250/50 mcg and 500/50 mcg) ...

LONDON, April 20, 2021 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that it has resumed the launch of its generic version of GlaxoSmithKline's ...

Advair 250/50 Now the Only Treatment Approved to Both Reduce Exacerbations and Improve Lung Function RESEARCH TRIANGLE PARK, N.C., May 1 -- Late yesterday the U.S. Food and Drug Administration ...

PHILADELPHIA, June 1, 2021 /PRNewswire/ -- Lannett Company, Inc. (NYSE: LCI) today announced the U.S. Food and Drug Administration (FDA) has accepted the Abbreviated New Drug Application (ANDA) for ...

Advair Diskus 250/50 is also indicated to reduce exacerbations in patients with a history of exacerbations. Advair Diskus 250/50 is the only approved strength for COPD because an efficacy advantage of ...